London, UK – 05 October 2017 – NetScientific plc (“NetScientific”, AIM:NSCI), the transatlantic healthcare IP commercialisation Group, announces that a Japanese patent exclusively licensed to one of its portfolio companies, Glycotest, has been granted. The patent protects fucosylated kininogen—a key biomarker in the Glycotest’s lead HCC Panel test for early-stage liver cancer.
This patent expands Glycotest’s patent portfolio which has 10 previously granted or allowed patents, protecting multiple aspects of Glycotest’s proprietary liver disease diagnostic platform, including over 50 unique glycoprotein biomarkers and the assay technology required to measure them. These patents have been licensed exclusively on a worldwide basis to Glycotest by Drexel University College of Medicine and the Blumberg Institute of the Hepatitis B Foundation, both located in the Philadelphia area.
As announced on 28 September 2017, the Company is on track to close a Series A round within the second half of 2017. Glycotest’ lead product, HCC panel, has demonstrated in two studies of 208 patients and 127 patients respectively that it has the potential to outperform the current dominant blood test (AFP) regarding the early detection of HCC in patients with cirrhosis.
NetScientific holds an 87.5% stake (67% on a fully diluted basis) in Glycotest.
Commenting on the news, NetScientific’s Chief Executive Officer and Chairman of Glycotest, Francois R. Martelet said: “We are very pleased to announce further strengthening of the IP landscape controlled by Glycotest in the field of liver diagnostics and we expect further positive developments for the intellectual property portfolio in the future. We also look forward to further clinical validation of the Glycotest platform in H2 2017.”
The full text of the announcement from Glycotest can be found below.
For more information please contact:
François R. Martelet, M.D., CEO
Ian Postlethwaite, CFO
Tel: +44 (0)20 3514 1800
Consilium Strategic Communications
Mary-Jane Elliott / Jessica Hodgson /
Chris Welsh / Laura Thornton
Tel: +44 (0)20 3709 5700
Stifel Nicolaus Europe Limited (NOMAD and Broker)
Jonathan Senior / David Arch / Ben Maddison
Tel: +44 (0) 20 7710 7600
Office: +1 646 722 4339
NetScientific is an IP commercialisation group focused on healthcare with an investment strategy focused on sourcing, funding and commercialising technologies that significantly improve the health and well-being of people with chronic diseases. For more information, please visit the website at www.netscientific.net
Glycotest™ Announces Grant of Japanese Patent
New York, NY— October 05, 2017—Glycotest, Inc. announced today that a Japanese patent protecting fucosylated kininogen—a key biomarker in the Company’s lead HCC Panel test for early-stage liver cancer—has been granted.
Glycotest is a private liver disease diagnostics company commercializing new and unique blood tests for liver cancers and fibrosis-cirrhosis. The Company’s mission is to reduce mortality and increase survival for the growing population at risk from serious liver diseases. Glycotest employs unique non-invasive blood tests based on proprietary serum biomarkers, biomarker panels and assay technology that exploit novel sugar-based disease signal chemistry.
The Japanese patent announced today is the latest in an expanding portfolio that now includes 10 granted or allowed patents protecting multiple aspects of Glycotest’s proprietary liver disease diagnostic platform, including over 50 unique glycoprotein biomarkers and the assay technology needed to measure them. These patents have been licensed exclusively and on a worldwide basis to Glycotest by Drexel University College of Medicine and the Blumberg Institute of the Hepatitis B Foundation, both in the Philadelphia area. Further expansion and strengthening of the Company’s intellectual property position is expected from applications pending in commercially important US and international jurisdictions.
Glycotest’s Chief Executive Officer Lawrence Cohen said, “This latest Japanese patent provides an important layer of protection for Glycotest’s lead HCC Panel test for early-stage liver cancer in a part of the world significantly impacted by this life-threatening disease. Glycotest is commercializing the HCC Panel test to provide physicians with a greatly needed to tool to identify patients eligible for life-saving curative therapy.”
About Glycotest, Inc.
Glycotest is a private liver disease diagnostics company commercializing novel clinical laboratory testing services for patients at risk for liver cancers and fibrosis-cirrhosis. The Company was founded in 2012 on proprietary technology that originated at the Philadelphia area institutions Baruch S. Blumberg Institute and Drexel University College of Medicine. Learn more at www.glycotest.com.